2023 - Research.com Medicine in Switzerland Leader Award
As part of his studies on Internal medicine, Oliver Distler frequently links adjacent subjects like Bedtime. The study of Bedtime is intertwined with the study of Internal medicine in a number of ways. In his papers, Oliver Distler integrates diverse fields, such as Randomized controlled trial and Placebo. He incorporates Placebo and Alternative medicine in his research. Oliver Distler undertakes multidisciplinary studies into Alternative medicine and Randomized controlled trial in his work. His Reflux study frequently draws connections between related disciplines such as Disease. In most of his Disease studies, his work intersects topics such as Reflux. Oliver Distler performs multidisciplinary studies into Ranitidine and Omeprazole in his work. Oliver Distler combines Omeprazole and Gastric acid in his studies.
His Receptor research is covered under the topics of Agonist and Serotonin. As part of his studies on Agonist, he frequently links adjacent subjects like Receptor. He regularly ties together related areas like Logistic regression in his Internal medicine studies. His Pathology study frequently links to other fields, such as Clinical trial. His Clinical trial study frequently draws connections between adjacent fields such as Pathology. Inoculation is closely attributed to Scleroderma (fungus) in his study. In most of his Scleroderma (fungus) studies, his work intersects topics such as Immunology. His Immunology study frequently links to related topics such as Inoculation. His multidisciplinary approach integrates Dermatology and Rheumatology in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson.
Arthritis & Rheumatism (2013)
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Anthony J. Tyndall;Bettina Bannert;Madelon Vonk;Paolo Airò.
Annals of the Rheumatic Diseases (2010)
Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis
David Hürlimann;Adrian Forster;Georg Noll;Frank Enseleit.
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka;Jaap Fransen;Jerome Avouac;Mike Becker;Mike Becker.
Annals of the Rheumatic Diseases (2015)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler;Martina Gahlemann;Toby M Maher.
The New England Journal of Medicine (2019)
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
Alfiya Akhmetshina;Katrin Palumbo;Clara Dees;Christina Bergmann.
Nature Communications (2012)
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
J Gerry Coghlan;Christopher P Denton;Ekkehard Grünig;Diana Bonderman.
Annals of the Rheumatic Diseases (2014)
Synovial fibroblasts: key players in rheumatoid arthritis
L. C. Huber;O. Distler;I. Tarner.
MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
Britta Maurer;Joanna Stanczyk;Astrid Jüngel;Alfiya Akhmetshina.
Arthritis & Rheumatism (2010)
Angiogenic and angiostatic factors in the molecular control of angiogenesis.
J H W Distler;A Hirth;M Kurowska-Stolarska.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: